Mabpharm 将来の成長

Future 基準チェック /06

We currently don't have sufficient analyst coverage to forecast growth and revenue for Mabpharm.

主要情報

n/a

収益成長率

n/a

EPS成長率

Biotechs 収益成長	41.8%
収益成長率	n/a
将来の株主資本利益率	n/a
アナリストカバレッジ	None
最終更新日	n/a

今後の成長に関する最新情報

更新なし

Recent updates

Shareholders May Be A Bit More Conservative With Mabpharm Limited's (HKG:2181) CEO Compensation For Now

Jun 14

More Unpleasant Surprises Could Be In Store For Mabpharm Limited's (HKG:2181) Shares After Tumbling 41%

Jan 24

Here's Why We're Not Too Worried About Mabpharm's (HKG:2181) Cash Burn Situation

Apr 28

Did You Miss Mabpharm's (HKG:2181) 14% Share Price Gain?

Mar 03

We're Not Very Worried About Mabpharm's (HKG:2181) Cash Burn Rate

Jan 27

Do Insiders Own Lots Of Shares In Mabpharm Limited (HKG:2181)?

Dec 09

このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Mabpharm は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。

シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。

業績と収益の成長予測

SEHK:2181 - アナリストの将来予測と過去の財務データ ( )CNY Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
6/30/2024	152	-207	2	27	N/A
3/31/2024	119	-208	20	42	N/A
12/31/2023	87	-209	38	57	N/A
9/30/2023	79	-202	-38	-11	N/A
6/30/2023	71	-194	-114	-79	N/A
3/31/2023	64	-202	-148	-68	N/A
12/31/2022	56	-211	-182	-57	N/A
9/30/2022	43	-237	-235	-80	N/A
6/30/2022	30	-263	-288	-102	N/A
3/31/2022	57	-278	-318	-151	N/A
12/31/2021	83	-292	-348	-199	N/A
9/30/2021	82	-284	-342	-185	N/A
6/30/2021	81	-276	-336	-171	N/A
3/31/2021	41	-230	-340	-159	N/A
12/31/2020	N/A	-185	-344	-147	N/A
9/30/2020	5	-163	-340	-147	N/A
6/30/2020	11	-141	-335	-146	N/A
3/31/2020	12	-172	-292	-141	N/A
12/31/2019	14	-203	-250	-137	N/A
9/30/2019	16	-208	-195	-113	N/A
6/30/2019	17	-212	-140	-89	N/A
3/31/2019	21	-169	-146	-76	N/A
12/31/2018	24	-125	-153	-62	N/A
12/31/2017	5	-31	N/A	-65	N/A

アナリストによる今後の成長予測

収入対貯蓄率: Insufficient data to determine if 2181's forecast earnings growth is above the savings rate (2.3%).

収益対市場: Insufficient data to determine if 2181's earnings are forecast to grow faster than the Hong Kong market

高成長収益: Insufficient data to determine if 2181's earnings are expected to grow significantly over the next 3 years.

収益対市場: Insufficient data to determine if 2181's revenue is forecast to grow faster than the Hong Kong market.

高い収益成長: Insufficient data to determine if 2181's revenue is forecast to grow faster than 20% per year.

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: Insufficient data to determine if 2181's Return on Equity is forecast to be high in 3 years time

Mabpharm 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

Recent updates

First half 2024 earnings released: CN¥0.024 loss per share (vs CN¥0.024 loss in 1H 2023)

Mabpharm Limited to Report First Half, 2024 Results on Aug 28, 2024

Mabpharm Limited Announces Resignation of Li Yunfeng as Chief Financial Officer

Mabpharm Limited Announces Resignation of Li Yunfeng as Chief Financial Officer

Mabpharm Limited Announces Approval from the Ministry of Health of Peru on the New Drug Application of CMAB008 (Infliximab for Injection)

Simcere Zaiming and Mabpharm Limited Announce Approval of Cetuximab Beta in China by the NMPA

Simcere Pharmaceutical Group Limited and Mabpharm Limited Announce Approval on the Marketing of ENLITUO in China by the National Medical Products Administration of China

Shareholders May Be A Bit More Conservative With Mabpharm Limited's (HKG:2181) CEO Compensation For Now

Mabpharm Limited, Annual General Meeting, Jun 21, 2024

Full year 2023 earnings released: CN¥0.05 loss per share (vs CN¥0.051 loss in FY 2022)

Mabpharm Limited to Report Fiscal Year 2023 Results on Mar 26, 2024

More Unpleasant Surprises Could Be In Store For Mabpharm Limited's (HKG:2181) Shares After Tumbling 41%

Mabpharm Limited Announces Director Changes

First half 2023 earnings released: CN¥0.024 loss per share (vs CN¥0.028 loss in 1H 2022)

Mabpharm Limited to Report First Half, 2023 Results on Aug 25, 2023

Full year 2022 earnings released: CN¥0.05 loss per share (vs CN¥0.071 loss in FY 2021)

Less than half of directors are independent

Mabpharm (HKG:2181) Is Making Moderate Use Of Debt

Mabpharm Limited to Report First Half, 2022 Results on Aug 26, 2022

Mabpharm Limited Approves the Clinical Trial Application of CMAB015 for the Treatment of Psoriasis and Ankylosing Spondylitis

Mabpharm Limited Announces Approval by National Medical Products Administration of China for the Clinical Trial Application of Biological Class I New Drug Cmab017

Less than half of directors are independent

Here's Why We're Watching Mabpharm's (HKG:2181) Cash Burn Situation

Mabpharm Limited Announces Approval of Clinical Trial Application of CMAB807X by the National Medical Products Administration of China

Here's Why We're Watching Mabpharm's (HKG:2181) Cash Burn Situation

First half 2021 earnings released: CN¥0.035 loss per share (vs CN¥0.013 loss in 1H 2020)

Here's Why We're Not Too Worried About Mabpharm's (HKG:2181) Cash Burn Situation

Mabpharm Limited to Report Fiscal Year 2020 Results on Mar 26, 2021

New 90-day high: HK$1.18

Did You Miss Mabpharm's (HKG:2181) 14% Share Price Gain?

We're Not Very Worried About Mabpharm's (HKG:2181) Cash Burn Rate

New 90-day low: HK$1.08

Do Insiders Own Lots Of Shares In Mabpharm Limited (HKG:2181)?

New 90-day low: HK$1.14

Mabpharm Limited Announces CEO Changes

New 90-day low: HK$1.15

Mabpharm Limited to Report First Half, 2020 Results on Aug 26, 2020

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘